What are the four primary medication classes recommended for chronic systolic heart failure?

The Four Pillars of Heart Failure Medications

The four primary medication classes for chronic systolic heart failure (HFrEF) are: (1) ACE inhibitors/ARBs/ARNi, (2) Beta-blockers, (3) Mineralocorticoid receptor antagonists (MRAs), and (4) SGLT2 inhibitors—all of which should be initiated rapidly and simultaneously at low doses, then uptitrated to target doses to reduce mortality and hospitalizations. 1

The Four Pillars Explained

1. Renin-Angiotensin System Inhibition

• ACE inhibitors are foundational therapy for all symptomatic HFrEF patients (NYHA class II-IV) to reduce morbidity and mortality 1
• ARNi (sacubitril/valsartan) is now preferred over ACE inhibitors as it further reduces HF hospitalization and death in ambulatory patients with HFrEF who remain symptomatic 1
• ARBs serve as alternatives when ACE inhibitors cause intolerable cough or angioedema and ARNi is not feasible 1
• Start with low doses and uptitrate to target doses used in major trials 1

2. Evidence-Based Beta-Blockers

• Only three beta-blockers have proven mortality reduction: bisoprolol, carvedilol, and metoprolol succinate (CR/XL) 1
• Recommended for all stable HFrEF patients (NYHA class II-IV) in addition to ACE inhibitors to reduce mortality and hospitalizations 1
• Beta-blocker benefits cannot be assumed as a class effect—use only the three proven agents 1
• Initiate at very low doses (bisoprolol 1.25 mg, carvedilol 3.125 mg twice daily, metoprolol CR/XL 12.5-25 mg) and double every 1-2 weeks to target doses 1

3. Mineralocorticoid Receptor Antagonists (MRAs)

• Spironolactone or eplerenone are recommended for NYHA class II-IV patients already on ACE inhibitors and beta-blockers to improve survival and reduce morbidity 1
• Particularly beneficial in advanced heart failure (NYHA III-IV) 1
• Requires estimated glomerular filtration rate >30 mL/min/1.73 m² and careful monitoring of potassium and renal function 1
• Avoid combining with potassium-sparing diuretics during ACE inhibitor initiation 1

4. SGLT2 Inhibitors

• Newest pillar added to guideline-directed medical therapy based on recent evidence 1, 2
• Recommended across the entire left ventricular ejection fraction spectrum, including HFrEF 2
• Provides additional mortality and hospitalization benefits when added to the other three pillars 1, 2
• Can be initiated early in the disease course 2

Implementation Strategy

Initiation Approach

• All four medications may be started simultaneously at initial low doses without waiting to achieve target dosing before initiating the next medication 1
• Alternatively, medications may be started sequentially based on clinical factors, though simultaneous initiation is increasingly preferred 1
• The ACE inhibitor (or ARNi) is typically initiated first, followed by beta-blocker, then MRA and SGLT2i 1

Uptitration Protocol

• Increase doses to target levels used in major clinical trials as tolerated 1
• Monitor blood pressure, heart rate, renal function, and electrolytes 1-2 weeks after each dose increment 1
• Lower doses still provide benefit if target doses are not tolerated—some therapy is better than no therapy 1

Critical Monitoring Parameters

• Check blood pressure, renal function (creatinine), and electrolytes (potassium, sodium) regularly during uptitration 1
• Avoid NSAIDs as they interfere with ACE inhibitor efficacy and worsen renal function 1
• If renal function deteriorates substantially, adjust or discontinue the offending agent 1

Additional Therapies (Not Part of the Four Pillars)

Diuretics

• Loop diuretics or thiazides are recommended for symptom relief and exercise capacity improvement in patients with signs/symptoms of congestion 1
• Always administered in addition to the four pillars, not as a replacement 1
• If GFR <30 mL/min, avoid thiazides except when used synergistically with loop diuretics 1

Digoxin

• Indicated for atrial fibrillation with any degree of symptomatic HF to slow ventricular rate 1
• In sinus rhythm, improves clinical status in patients with persistent symptoms despite optimal therapy 1
• Usual dose 0.125-0.25 mg daily (lower in elderly: 0.0625-0.125 mg) 1

Common Pitfalls to Avoid

• Do not assume beta-blocker benefits are a class effect—only bisoprolol, carvedilol, and metoprolol CR/XL have proven mortality reduction 1
• Avoid combining ACE inhibitor + ARB + MRA due to increased risk of renal dysfunction and hyperkalemia 1
• Do not use diltiazem or verapamil in HFrEF as they increase risk of HF worsening and hospitalization 1
• Do not delay initiation of all four pillars—early comprehensive therapy improves outcomes 1, 3
• Monitor for hyperkalemia when combining ACE inhibitors/ARNi with MRAs, especially with renal impairment 1

Real-World Implementation Gap

Despite strong guideline recommendations, real-world data shows significant underutilization: within 3 months of HFrEF diagnosis, only 93% receive RASI/ARNi, 92% receive beta-blockers, 35% receive MRA, and 26% receive SGLT2i 3. This represents a major opportunity for improving outcomes through better implementation of guideline-directed medical therapy 3, 4.